Recently, investigators demonstrated the feasibility of gathering data on several key gout treatment quality indicators from EMRs. Using 10 quality indicators for gout care established more than a dozen years ago, they found that although some quality indicators are easy to assess with EMRs, others are difficult.
A retrospective chart review paints a glowing portrait of the effects of belimumab in patients with systemic lupus erythematosus (SLE). The biologic medication was associated with significant reduction in disease severity and glucocorticoid dose, according to the researchers.
Whistler, BC—Rituximab plus methotrexate is well tolerated in patients with moderate-to-severe, active rheumatoid arthritis (RA) who take the medications for up to 11 years, according to recent research.
Whistler, BC—An observational study confirms in a real-world setting that people with rheumatoid arthritis (RA) who have low disease activity (LDA) after 6 months of biologic treatment are very likely to achieve remission within the next 6 months.
A pair of posters presented at this year’s Canadian Rheumatology Association Annual Scientific Meeting suggest that rheumatologic diseases are associated with proximity to major industrial emitters and exposure to sources of fine particulate matter air pollution.
The first large study of pregnancy outcomes among women with childhood-onset systemic lupus erythematosus (cSLE) demonstrates a high incidence of stillbirths and spontaneous abortions. These data are similar in women with adult-onset SLE.
Ottawa, Ontario—A simple questionnaire can help clinicians track adverse events (AEs) and plan medication adjustments in patients receiving biologic drug therapy, according to researchers at The Hospital for Sick Children in Toronto, Ontario, who presented at the recent Canadian Rheumatology Association annual meeting. By Rosemary Frei, MSc
A new study confirms that people with rheumatoid arthritis (RA) have a higher risk of developing diabetes mellitus (DM) compared with the general population.
A retrospective chart review paints a glowing portrait of the effects of belimumab in patients with systemic lupus erythematosus (SLE). The biologic medication was associated with significant reduction in disease severity and glucocorticoid dose, according to the researchers.
Certain statins may have the potential to reduce people’s risk of developing rheumatoid arthritis (RA), according to a case-control analysis presented at the Canadian Rheumatology Association’s 2015 Annual Scientific Meeting.
Page 1 of 2
Results 1 - 10 of 12
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology